Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gadolinium as a neutron capture therapy agent.

J L Shih1, R M Brugger

  • 1Nuclear Engineering Program, University of Missouri-Columbia 65211.

Medical Physics
|May 1, 1992
PubMed
Summary

Gadolinium-157 shows promise as a neutron capture therapy agent for brain tumors. This method can deliver significant radiation doses to tumors, comparable to Boron neutron capture therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vascular endothelial growth factor expression by hyalocytes and its regulation by glucocorticoid.

The British journal of ophthalmology·2008
Same author

Boron neutron capture therapy of brain tumors: past history, current status, and future potential.

Cancer investigation·1996
Same author

Physical and biological doses produced from neutron capture in a 235U foil.

Medical physics·1995
Same author

Design of a high-flux epithermal neutron beam using 235U fission plates at the Brookhaven Medical Research Reactor.

Medical physics·1994
Same author

Enhancement of the epithermal neutron beam used for boron neutron capture therapy.

International journal of radiation oncology, biology, physics·1994
Same author

Boron neutron capture therapy for cancer. Realities and prospects.

Cancer·1992

Area of Science:

  • Medical Physics
  • Oncology
  • Radiochemistry

Background:

  • Boron neutron capture therapy (BNCT) shows encouraging clinical results for brain tumors.
  • Researchers are actively developing novel therapeutic modalities for cancer treatment.
  • Gadolinium-157 (Gd-157) is a promising nuclide for neutron capture therapy due to its nuclear properties.

Purpose of the Study:

  • To evaluate the potential of Gadolinium-157 as a neutron capture therapy agent.
  • To determine achievable Gadolinium concentrations in tumors using MRI contrast agents.
  • To assess the dose distribution and therapeutic efficacy of Gd-157 neutron capture therapy.

Main Methods:

  • Monte Carlo simulations were used to calculate radiation dose deposition.
  • Tumor concentrations of Gd-157 were estimated using MRI contrast agents (Gd-DTPA, Gd-DOTA, Gd-EDTMP).
  • Dose measurements in phantoms using films and thermoluminescent dosimeters (TLDs) verified simulation results.

Main Results:

  • Estimated tumor concentrations of up to 300 µg 157Gd/g for brain tumors and 800 µg 157Gd/g for bone tumors.
  • Monte Carlo calculations indicate that 250 ppm of 157Gd can deliver 2000 cGy to a 2-cm tumor with a thermal neutron fluence of 5 x 10^12 n/cm².
  • Gd-157 neutron capture therapy demonstrated dose distribution comparable to BNCT.
  • Auger electrons from Gd-157 contributed to dose enhancement, similar to prompt gamma dose.

Conclusions:

  • Gadolinium-157 is a viable agent for neutron capture therapy, particularly for brain and bone tumors.
  • The therapeutic potential of Gd-157 neutron capture therapy is comparable to BNCT.
  • Further research into Gd-157 neutron capture therapy could lead to enhanced treatment outcomes for various tumors.

Related Experiment Videos